Hadil Es-Sbai is President and Executive Director at Triall, a digital ecosystem of blockchain-enabled software solutions that offers data integrity, audibility and operational efficiency in clinical trials. In addition, he is the CEO of CR2O, a full service contract research organization with unique access to science, clinical services and subject populations within infectious disease/vaccine research/oncology and immunology. Hadil has over 20 years of experience in clinical development and assumed several roles within the pharmaceutical and clinical contract research industries. He has acquired extensive expertise managing international clinical trials within a wide range of therapeutic areas. A known founder of multiple successful service companies in the life sciences, all of his entrepreneurial initiatives are geared towards making innovative treatments accessible to those in need.
Since becoming an entrepreneur in 2006, Hadil has acquired expertise in business development and innovation in the pharma and clinical domain.
He was Managing Director of Assign Group's Benelux Development, responsible for the overall management of the Benelux affiliate.
He was Global Operations Study Leader at Grunenthal, responsible for overseeing the completion of two Phase II Pain trials.
Master's Degree, Analytical Chemistry, Vrije Universiteit
Bachelor's Degree, Analytical Chemistry, Saxion University
Hadil has appeared as a guest on Real Vision.